engleski

Combined chelation therapy in reducing tissue lead concentrations in suckling rats

The very young are more prone to lead poisoning than adults, and the treatment with chelating agents, either as monotherapy or combined treatment, is still a matter of dispute. The purpose of this work was to evaluate the efficiency of three chelating agents administered either as monotherapies or as combined treatments in sucklings. Lead acetate (5 mg Pb/kg i.p.) was administered to the seven-day-old rat pups in eight litters on the experimental day one, and chelating agents on experimental day two and three. Pups were divided into six groups: 1) untreated control ; 2) EDTA (CaNa2 ethylendiaminetetraacetate, 0.3 mmol/kg i.p. at 4 p.m.) ; 3) meso-DMSA (meso-2, 3-dimeracaptosuccinic acid, 0.5 mmol/kg p.o. at 10 a.m.) ; 4) rac-DMSA (rac-2, 3-dimeracaptosuccinic acid, 0.5 mmol/kg p.o. at 10 a.m.) ; 5) EDTA+ meso-DMSA ; 6) EDTA+rac-DMSA. Rats were killed on experimental day five. Tissue element concentrations were analyzed by AAS. Treatment with EDTA did not affect tissue Pb, but it reduced Zn in the carcass and liver. Meso-DMSA reduced Pb in the kidneys and brain, and it did not affect organ essential elements. Rac-DMSA most efficiently reduced Pb concentrations in the carcass, kidneys and brain, but it also reduced Zn and Cu in the liver and Zn in the kidneys. Combined treatments with EDTA never improved efficiency of either DMSA isoform in decreasing tissue Pb, but reduced tissue Zn concentrations. All treatments caused the same decrease in the carcass Ca concentrations. The results do not support combined treatment in this age group, especially sensitive to trace element deficiencies, and suggest that meso-DMSA might be the treatment of choice in acute lead poisoning in infants.

chelating agents; CaNa2EDTA; meso-DMSA; racemic-DMSA; monotherapy; combined treatment; lead poisoning; tissue element concentrations

nije evidentirano